- Home
- RCT vs BMEA Comparison
RCT vs BMEA Comparison
Compare RCT & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RCT
- BMEA
- Stock Information
- Founded
- RCT 2014
- BMEA 2017
- Country
- RCT United Kingdom
- BMEA United States
- Employees
- RCT N/A
- BMEA N/A
- Industry
- RCT
- BMEA Biotechnology: Pharmaceutical Preparations
- Sector
- RCT
- BMEA Health Care
- Exchange
- RCT NYSE
- BMEA Nasdaq
- Market Cap
- RCT 72.1M
- BMEA 65.8M
- IPO Year
- RCT 2025
- BMEA 2021
- Fundamental
- Price
- RCT $1.53
- BMEA $1.81
- Analyst Decision
- RCT Strong Buy
- BMEA Strong Buy
- Analyst Count
- RCT 2
- BMEA 10
- Target Price
- RCT $5.00
- BMEA $22.30
- AVG Volume (30 Days)
- RCT 25.4K
- BMEA 5.2M
- Earning Date
- RCT 05-17-2025
- BMEA 07-30-2025
- Dividend Yield
- RCT N/A
- BMEA N/A
- EPS Growth
- RCT N/A
- BMEA N/A
- EPS
- RCT N/A
- BMEA N/A
- Revenue
- RCT $46,499,285.00
- BMEA N/A
- Revenue This Year
- RCT N/A
- BMEA N/A
- Revenue Next Year
- RCT N/A
- BMEA N/A
- P/E Ratio
- RCT N/A
- BMEA N/A
- Revenue Growth
- RCT 134.76
- BMEA N/A
- 52 Week Low
- RCT $1.17
- BMEA $1.29
- 52 Week High
- RCT $5.00
- BMEA $13.07
- Technical
- Relative Strength Index (RSI)
- RCT N/A
- BMEA 44.35
- Support Level
- RCT N/A
- BMEA $2.24
- Resistance Level
- RCT N/A
- BMEA $3.08
- Average True Range (ATR)
- RCT 0.00
- BMEA 0.40
- MACD
- RCT 0.00
- BMEA -0.03
- Stochastic Oscillator
- RCT 0.00
- BMEA 25.07
About RCT REDCLOUD HOLDINGS PLC
RedCloud Holdings PLC developed and operates the RedCloud Platform, which facilitates the trading of everyday consumer supplies of fast-moving consumer goods (FMCG) products across business supply chains. The Platform solves old problem of how to unlock and enable access of key purchase and sales data between brands, distributors and retailers in growth consumer markets. Its Platform has AI and machine learning capabilities that provide brands, distributors and retailers with trading and product insights and data to help make commercial decisions regarding their business operations. Geographically, Key revenue is generated from Nigeria.
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.